Pomalidomideis effective for prevention and treatment of experimental skin fibrosis

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1895-1899

  Weingärtner, Simon ^a   Zerr, Pawel ^a   Tomcik, Michal ^a   Palumbo Zerr, Katrin ^a   Distler, Alfiya ^a   Dees, Clara ^a   Beyer, Christian ^a   Shankar, Sai L ^b   Cedzik, Dorota ^b   Schafer, Peter H ^b   Distler, Oliver ^c   Schett, Georg ^a   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b CELGENE CORPORATION   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; HYDROXYPROLINE; POMALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COL1A1 GENE; CONTROLLED STUDY; CTGF GENE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FIBROBLAST; GENE; MOUSE; MYOFIBROBLAST; NONHUMAN; PAI 1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SKINFOLD THICKNESS; ANIMAL; CHEMICALLY INDUCED DISORDER; DBA MOUSE; DISEASE MODEL; FIBROSIS; METABOLISM; MOUSE MUTANT; PATHOLOGY; SKIN; SKIN DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; HYDROXYPROLINE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED DBA; MICE, MUTANT STRAINS; MYOFIBROBLASTS; SKIN; SKIN DISEASES; THALIDOMIDE;

EID: 84867404501     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201784     Document Type: Article

References (20)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360 :1989-2003.
2. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32: S24-30. (Pubitemid 41111987)
3. Galustian C, Dalgleish AC. Pomalidomide. Drugs of the Future 2011;6:741-50.
4. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6. (Pubitemid 29295864)
5. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-16.
6. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276 :22382-7.
7. Xu W, Celeridad M, Sankar S, et al. CC-4047 promotes Th1 cell differentiation and reprograms polarized human Th2 cells by enhancing transcription factor T-bet. Clin Immunol 2008;128:392-9.
8. Beyer C, Schett G, Distler O, et al. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62:2831-44.
9. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208:961-72.
10. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
11. Avouac J, Furnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2012;63:800-9.
12. Avouac J, Palumbo K, Tomcik M, et al . Inhibition of AP-1 signaling abrogates TGF-ss mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2011;64:1642 -52.
13. Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771-9.
14. Choe JY, Jung HJ, Park KY, et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010;59:177-88.
15. Mall JW, Schwenk W, Philipp AW, et al. Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits. Eur J Surg 2002;168:641 -5.
16. Muriel P, Fernandez-Martinez E, Perez-Alvarez V, et al. Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat. Eur J Gastroenterol Hepatol 2003;15:951-7. (Pubitemid 37094293)
17. Yndestad A, Vinge LE, Bjornerheim R, et al. Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. Eur J Heart Fail 2006;8:790-6. (Pubitemid 44779411)
18. Zhao L, Xiao K, Wang H, et al. Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies. Clin Exp Immunol 2009;157:310-15.
19. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000;97:109-20.
20. Pusic I, DiPersio JF, Goran SL. Phase 2 study of pomalidomide in advanced corticosteroid-resistant chronic graft-versus-host disease (cGVHD). American Society of Hematology 51st Annual Meeting and Exposition 2009; December 7.